Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Long-term prevention of hypertension and end-organ damage in Ren-2 transgenic rats is achieved only with persistent but not transient AT1 receptor blockade

Vanecková I., Kopkan L., Husková Z., Vanourková Z., Schejbalová S., Cervenka L., Kramer H.J.

. 2007 ; 30 (1) : 38-44.

Jazyk angličtina Země Švýcarsko

Perzistentní odkaz   https://www.medvik.cz/link/bmc07526849

Grantová podpora
NR8550 MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Část
Zdroj

E-zdroje Online

NLK Karger Journals od 1996 do 2009
ProQuest Central od 1994-05-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2005-01-01
Health & Medicine (ProQuest) od 1994-05-01 do Před 1 rokem
ROAD: Directory of Open Access Scholarly Resources od 1996

The aim of this study was first to evaluate the effects of persistent or transient blockade of the angiotensin II (ANG II) receptor AT(1) on the development of hypertension and end-organ damage in hypertensive Ren-2 transgenic rats (TGR), and second to assess the potential role of AT(2) receptors in the control of blood pressure (BP) in this monogenetic model of hypertension. Male heterozygous TGR and Hannover Sprague-Dawley (HanSD) rats fed a normal salt diet were treated from day 32 of age either persistently until the end of the experiment (day 100 of age) or transiently until day 56 of age with the selective AT(1) receptor antagonist candesartan or with the combination of candesartan and the AT(2) receptor antagonist PD 123319. Persistent treatment with candesartan completely prevented the rise in BP, proteinuria and the increase in left ventricular weight/body weight ratio, whereas transient treatment with candesartan was effective only as long as the drug was administered. In the presence of candesartan, PD 123319 was without effect. Our results show that in male heterozygous TGR persistent candesartan treatment completely prevented hypertension and end-organ damage as long as the drug was administered, whereas transient AT(1 )receptor blockade had no long-term effects. Copyright 2007 S. Karger AG, Basel.

000      
00000naa 2200000 a 4500
001      
bmc07526849
003      
CZ-PrNML
005      
20131007090506.0
008      
090802s2007 sz e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Vaněčková, Ivana, $d 1964- $7 xx0030586
245    10
$a Long-term prevention of hypertension and end-organ damage in Ren-2 transgenic rats is achieved only with persistent but not transient AT1 receptor blockade / $c Vanecková I., Kopkan L., Husková Z., Vanourková Z., Schejbalová S., Cervenka L., Kramer H.J.
314    __
$a Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
520    9_
$a The aim of this study was first to evaluate the effects of persistent or transient blockade of the angiotensin II (ANG II) receptor AT(1) on the development of hypertension and end-organ damage in hypertensive Ren-2 transgenic rats (TGR), and second to assess the potential role of AT(2) receptors in the control of blood pressure (BP) in this monogenetic model of hypertension. Male heterozygous TGR and Hannover Sprague-Dawley (HanSD) rats fed a normal salt diet were treated from day 32 of age either persistently until the end of the experiment (day 100 of age) or transiently until day 56 of age with the selective AT(1) receptor antagonist candesartan or with the combination of candesartan and the AT(2) receptor antagonist PD 123319. Persistent treatment with candesartan completely prevented the rise in BP, proteinuria and the increase in left ventricular weight/body weight ratio, whereas transient treatment with candesartan was effective only as long as the drug was administered. In the presence of candesartan, PD 123319 was without effect. Our results show that in male heterozygous TGR persistent candesartan treatment completely prevented hypertension and end-organ damage as long as the drug was administered, whereas transient AT(1 )receptor blockade had no long-term effects. Copyright 2007 S. Karger AG, Basel.
650    _2
$a financování organizované $7 D005381
650    _2
$a blokátory receptorů AT1 pro angiotensin II $x farmakologie $7 D047228
650    _2
$a zvířata $7 D000818
650    _2
$a geneticky modifikovaná zvířata $7 D030801
650    _2
$a benzimidazoly $x farmakologie $7 D001562
650    _2
$a krevní tlak $7 D001794
650    _2
$a renální hypertenze $x farmakoterapie $7 D006977
650    _2
$a ledviny $x patofyziologie $7 D007668
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a proteinurie $x moč $7 D011507
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Sprague-Dawley $7 D017207
650    _2
$a receptor angiotensinu typ 1 $x metabolismus $7 D044140
650    _2
$a receptor angiotensinu typ 2 $x fyziologie $x krev $x metabolismus $7 D044139
650    _2
$a renin $x genetika $7 D012083
650    _2
$a tetrazoly $x farmakologie $7 D013777
700    1_
$a Kopkan, Libor $7 xx0107287
700    1_
$a Husková, Zuzana, $d 1978- $7 xx0074206
700    1_
$a Vaňourková, Zdeňka, $d 1973- $7 xx0074217
700    1_
$a Schejbalová, Stanislava $7 xx0134795
700    1_
$a Červenka, Luděk, $d 1967- $7 xx0037105
700    1_
$a Kramer, Herbert J. $7 xx0085908
773    0_
$w MED00003064 $t Kidney & blood pressure research $g Roč. 30, č. 1 (2007), s. 38-44 $x 1420-4096
910    __
$a ABA008 $b x $y 7 $z 0
990    __
$a 20090726182400 $b ABA008
991    __
$a 20131007091027 $b ABA008
999    __
$a ok $b bmc $g 670865 $s 530014
BAS    __
$a 3
BMC    __
$a 2007 $b 30 $c 1 $d 38-44 $i 1420-4096 $m Kidney & blood pressure research $x MED00003064
GRA    __
$a NR8550 $p MZ0
LZP    __
$a 2009-B3/vtme

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...